HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.

Trial Details

NCT ID
NCT06770452
Phase
PHASE2
Sponsor
Zhejiang University
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • HRS-4642
  • Nimotuzumab
  • gemcitabine + nab-paclitaxel
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Age: 18-75 (including 18 and 75); 2.Metastatic pancreatic cancer (from pancreatic ductal epithelium) for Arm A; Locally advanced pancreatic cancer …
  • Neutrophil count≥1.5×10\^9 / L;
  • Platelet≥100×10\^9 / L;
  • Hemoglobin≥100 g / L;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →